Key Highlights

  • Corcept Therapeutics grew second-quarter product Revenue 32% to about $256.1 million, with Net Income near $43.0 million.
  • Biogen's second-quarter revenue rose 3% to about $2.74 billion, with Alzheimer's therapy Leqembi contributing roughly $184 million.
  • Kura Oncology's Komzifti (ziftomenib) won FDA approval on November 13, 2025, marking its move from clinical-stage to commercial.
  • Beam Therapeutics holds about $1.2 billion in cash, with runway guided into mid-2029 as it advances base-editing therapies.

Biotech rarely moves as a bloc. It moves as a collection of binary events, a trial readout here, a regulatory decision there, that happen to sit under the same index. That is exactly why Galectin Therapeutics (NASDAQ:GALT), Biogen (NASDAQ:BIIB), Corcept Therapeutics (NASDAQ:CORT), Kura Oncology (NASDAQ:KURA) and Beam Therapeutics (NASDAQ:BEAM) are worth grouping this September. Each trades on the Nasdaq. Each sits at a different point on the risk curve: a micro-cap chasing a single Phase 3, a large-cap rebuilding around new launches, a profitable specialist expanding its label, a newly commercial oncology company, and a gene-editing platform still years from broad revenue. Together they map how the sector is being valued as the Federal Reserve's mid-September meeting approaches. Every figure below traces to a listed source.

The Sector Backdrop: Catalysts Over Macro, but Rates Still Loom

Biotech spent much of 2025 and 2026 trying to shake off a multi-year funding hangover, and the tone heading into autumn is cautiously constructive rather than euphoric. Two forces dominate.

The first is monetary. The Federal Open Market Committee is scheduled to meet on September 15-16, 2026. Rate expectations matter disproportionately for biotech because pre-revenue companies are long-duration assets: their value sits in cash flows years out, so a lower discount rate lifts them more than most sectors, while a higher-for-longer stance punishes the cash-burning names first. That dynamic is the connective tissue between a Beam or a Galectin and a profitable Corcept or Biogen.

The second force is idiosyncratic catalysts, FDA decisions, pivotal data, launches. Those are what actually re-rate individual tickers, and the five names here Supply a dense calendar of them. The following sections take each company in turn.

Galectin Therapeutics (NASDAQ:GALT): A Micro-Cap's High-Stakes Liver Bet

Galectin is developing belapectin for MASH cirrhosis with portal hypertension, advanced fatty-liver disease with dangerously high pressure in the portal vein. In 2025 the company reported top-line results from its Phase 2b/3 NAVIGATE trial and later published them in the Journal of Hepatology, and it presented additional analyses at EASL 2026. Crucially, Galectin announced a positive Type C meeting with the FDA, saying it reached agreement on the primary endpoint and regulatory path: a composite liver outcome that includes preventing large esophageal varices (greater than 5 mm), pursued through the traditional (not accelerated) approval route. The company said it submitted its Phase 3 protocol and plans a randomized, double-blind, placebo-controlled study using a single 2 mg dose. For the quarter ended June 30, 2026, Galectin reported a net loss of about $9.2 million and roughly $13.3 million in cash.

This is the highest-variance name in the group. Belapectin would address a serious unmet need, and FDA endpoint alignment removes one large uncertainty. But the roughly $13 million cash balance against a Phase 3 program is the story's fault line, Galectin has openly pointed to strategic and financing partnerships.

If a partner or financing arrives, sentiment could improve sharply; without one, dilution or delay risk dominates. Watch for funding news before the trial itself.

Biogen (NASDAQ:BIIB): The Large-Cap Trying to Reaccelerate

Biogen reported second-quarter 2026 total revenue of about $2.74 billion, up 3% year over year and ahead of consensus, with adjusted EPS of $3.60. Alzheimer's therapy Leqembi, recorded by partner Eisai, generated roughly $184 million in global revenue in the quarter, up about 15%, with U.S. sales near $97 million. Newer launches contributed: Skyclarys reached about $167.9 million (up 29%), and postpartum-depression drug Zurzuvae rose about 53% to roughly $70.8 million, while Spinraza held near $401.9 million. Biogen raised its 2026 outlook, guiding to a mid-single-digit percentage revenue increase from 2025 and lifting adjusted EPS guidance to a range of about $15.85 to $16.85 (Biogen Q2 2026 results, via reputable aggregators).

Biogen's Investment case has shifted from "will multiple sclerosis erode?" to "can the growth portfolio outrun that erosion?" The raised guidance and beats suggest the newer drugs are gaining traction, and Leqembi remains the long-term neuroscience option even as its ramp stays gradual.

Direction hinges on Leqembi's real-world adoption curve and continued momentum from Skyclarys and Zurzuvae. Execution, not a single binary, drives this one.

Corcept Therapeutics (NASDAQ:CORT): Cortisol Franchise, New Labels

Corcept reported second-quarter 2026 total product revenue of about $256.1 million, up 32% year over year, with net income near $43.0 million ($0.36 diluted EPS) and roughly $544.6 million in cash and investments. Legacy Cushing's drug Korlym and its authorized generic contributed about $208.6 million, while newly launched Lifyorli (relacorilant) added roughly $47.6 million in early sales. The company raised full-year 2026 revenue guidance to about $1.1–$1.2 billion. Lifyorli was approved in 2026 in combination with nab-paclitaxel for platinum-resistant ovarian cancer, and Corcept said more than 1,300 patients had started treatment. Separately, Corcept resubmitted its relacorilant NDA for Cushing's syndrome on June 17, 2026, expecting a roughly six-month review (aggregator reporting cited a PDUFA date around December 17, 2026), supported by the GRACE and GRADIENT Phase 3 trials.

Corcept is the group's profitable operator, and its cortisol-modulation science is now diversifying beyond endocrinology into oncology. The Cushing's resubmission is a near-term regulatory catalyst layered on an already-growing base.

A December Cushing's decision and the Lifyorli oncology ramp are the swing factors; guidance suggests management sees momentum continuing.

Kura Oncology (NASDAQ:KURA): From Clinical Stage to Commercial

With partner Kyowa Kirin, Kura won FDA approval of Komzifti (ziftomenib) on November 13, 2025, for adults with relapsed or refractory NPM1-mutant acute myeloid leukemia, a first-and-only once-daily menin inhibitor for that setting. The FDA cited the KO-MEN-001 trial (112 adults), which showed a combined complete-remission-plus-CRh rate of 21.4%, at 600 mg once daily. The drug launched on November 21, 2025, and Kura reported about $2.1 million in net product revenue in the five-week stub period ended December 31, 2025, alongside roughly $667.3 million in cash. For 2026, Kura pointed to further KOMET-007 combination data, advancing the KOMET-017 Phase 3 front-line AML trials, expansion into GIST, and about $45–$55 million in non-cash collaboration revenue.

Kura has crossed the hardest threshold in biotech, its first approval, and is now a commercial company with a strong cash cushion. The larger prize is front-line AML, where the KOMET-017 program could dramatically expand the addressable population if the data hold.

The 2026 story is early launch uptake plus front-line combination readouts; the Phase 3 program is the multi-year value driver, and it carries real trial risk.

Beam Therapeutics (NASDAQ:BEAM): Base Editing Reaches the Clinic in Earnest

Beam, a base-editing pioneer, reported roughly $1.2 billion in cash and marketable securities as of June 30, 2026, with runway guided into mid-2029 including a $200 million credit-facility draw. It said the first patient was dosed in the global pivotal cohort of the BEAM-302 trial for alpha-1 antitrypsin deficiency in July 2026, with updated data selected for a late-breaking oral presentation at the ERS Congress (September 5-9, 2026). For sickle cell disease, Beam said dosing was complete for all adult and adolescent patients in the Phase 1/2 BEACON trial of risto-cel, with a BLA submission possible as early as year-end 2026. Its BEAM-304 program for PKU cleared FDA IND clearance in June 2026, and initial BEAM-301 (GSDIa) data are expected in 2026. Second-quarter 2026 net loss was about $122.7 million ($1.18 per share).

Beam is the platform bet: multiple shots on goal across genetic diseases, a well-funded balance sheet, and the scientific distinction of editing single DNA bases rather than cutting the genome. That breadth is both the appeal and the burn.

The AATD pivotal cohort and a potential sickle cell BLA are the near-term inflection points; a well-received ERS presentation could shift sentiment, but the model still depends on clinical execution.

What Investors Should Watch

The near-term calendar is unusually concrete. Watch the FOMC's September 15-16 decision for the discount-rate signal that most affects the cash-burning names, Galectin and Beam. Watch Galectin for financing or Partnership news that would de-risk its Phase 3. Watch Corcept's relacorilant Cushing's review, expected to resolve around December, plus the Lifyorli oncology ramp. Watch Kura's early Komzifti launch metrics and front-line AML data. Watch Beam's ERS presentation and any movement toward a sickle cell BLA. And watch Biogen's newer launches for proof the growth portfolio can outrun legacy MS erosion.

Risks cut the other way just as sharply: trial failures, regulatory setbacks, dilutive financings for the smaller names, launch disappointments, and a Fed that stays restrictive. None of these outcomes is knowable in advance, which is precisely why position sizing matters more than conviction in biotech.

Five Points on the Biotech Risk Curve

Looked at together, these five tickers are not a theme so much as a cross-section. Galectin is a binary funding-and-data story; Biogen an execution turnaround; Corcept a profitable Franchise widening its labels; Kura a fresh commercial entrant; Beam a long-duration platform. What they share is that their moves this autumn will be driven by company-specific catalysts far more than by the index around them, with the Fed setting the backdrop. Investors are best served by tracking the individual calendars, distinguishing confirmed facts from hopeful narratives, and remembering that in biotech the next data point, not the last one, sets the price.